Evidence map›Paper›PMID 32265210›Full record

ArticleBMJ case reports2020

Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.

Oriol Mirallas, David Marmolejo, Augusto Valdivia, Maria Vieito

Open access · greenAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Oriol MirallasMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain urimirallas@gmail.com.ORCID http://orcid.org/0000-0002-8492-5195
David MarmolejoMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Augusto ValdiviaMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Maria VieitoMedical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Vall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meningioma, the second most common primary tumour of the central nervous system, is classified into three different grades based on their characteristics. Each tumour grade includes different molecular subtype, growth potential, and thus, different prognosis. Grade I meningioma is the most common subtype with a benign course, in which systemic dissemination rarely occurs. We present the case of a 48-year-old male patient with a history of grade I meningioma who was referred 3 years after the initial diagnosis to our centre due to pelvic pain. Computed tomography (CT) images showed new pelvic bone lesions whose histopathological report was compatible with a grade I meningioma. Neither hormonal therapy concomitant with octreotide nor hydroxiurea treatments were effective. Very little is known about this entity's prevalence and treatment when disseminated disease occurs. Thus, we think it is important to increase the positive and negative clinical experiences in this setting.

Indexed as

Antineoplastic Agents, HormonalBone Density Conservation AgentsBone DiseasesDisease ProgressionDrug Therapy, CombinationEstrogen AntagonistsFatal OutcomeHumansMaleMeningeal NeoplasmsMeningiomaMiddle AgedNeoplasm GradingOctreotidePelvic PainPelvisAntineoplastic Agents, HormonalBone Density Conservation AgentsEstrogen AntagonistsOctreotideTamoxifenZoledronic Acidcancer - see oncologyCNS cancerneurooncologyneurosurgeryradiotherapy

Identifiers

PMID32265210
PMCPMC7244284
OpenAlexW3014328759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.